Dassault Systèmes Invests in Click Therapeutics to Advance Digital Therapeutics Beyond Clinical Trials
核心洞察
Dassault Systèmes (搜索) has announced a strategic investment in Click Therapeutics (搜索), strengthening their existing relationship to expand digital therapeutics beyond clinical trials into real-world patient care.
The partnership aims to establish a unified platform for digital and pharmaceutical clinical trials, creating pathways for Prescription Digital Therapeutics (搜索) (PDTs) and Software-Enhanced (SE) product approvals.
This collaboration leverages Medidata's experience from over 8,000 annual clinical studies to extend patient engagement from trials through commercialization, responding to increased interest following recent FDA guidance on software-enhanced medications.
Dassault Systèmes (搜索) announced on March 19, 2025, a strategic investment in Click Therapeutics (搜索), a leader in prescription digital therapeutics (搜索) and software-enhanced drug therapies (搜索). This transaction strengthens the existing relationship between Dassault's MEDIDATA brand and Click Therapeutics, with the goal of transforming patient experience in healthcare through comprehensive technology solutions.
The investment comes at a pivotal time as digital therapeutics gain momentum in the pharmaceutical industry, offering new approaches to enhance traditional drug treatments and create novel therapeutic options.
Strategic Partnership Goals
The collaboration aims to improve patient engagement beyond clinical trials and into commercialization phases. By combining MEDIDATA's clinical research virtualization capabilities with Click Therapeutics (搜索)' digital therapeutic expertise, the partnership seeks to establish a unified offering for digital and pharmaceutical clinical trials.
"Digital therapeutics are beginning to transform the way customers think about their future clinical development programs and are providing demonstrable therapeutic benefits over drugs alone in many cases," said Anthony Costello, CEO of Medidata. "Today's investment in Click Therapeutics (搜索) reflects our commitment to this exciting technology, and our partnership with them will enable our customers to take the fastest, most reliable path to bringing digital therapeutics to patients, helping to build a direct connection to patients over a life-long healthcare journey."
The partnership will focus on creating pathways for Prescription Digital Therapeutics (搜索) (PDTs) and Software-Enhanced (SE) product approvals, expanding labels for existing therapeutics, and establishing a pipeline for long-term, real-world evidence generation.
Expanding the Digital Therapeutics Landscape
MEDIDATA brings substantial experience to the partnership, currently running over 8,000 active studies annually. This foundation allows the combined entities to extend their commitment to patients from clinical research into real-world care settings, fostering improved coordination between patients, physicians, caregivers, and life science manufacturers.
David Benshoof Klein, CEO of Click Therapeutics (搜索), noted increased industry interest following recent regulatory developments: "Since the FDA shared its latest thinking on Prescription Drug Use-Related Software (搜索) in guidance, we have experienced a surge in interest in how software can add to the benefits of medication. Now is the time to expand treatment options for patients through software as medicine."
Implications for Patient Care
The investment represents a significant step toward integrating digital therapeutics into mainstream healthcare. Click Therapeutics (搜索) will gain access to Dassault Systèmes (搜索)' global presence and expertise, while both companies will provide support for developing PDTs and software-enhanced products.
This collaboration comes as the healthcare industry increasingly recognizes the potential of digital interventions to complement traditional pharmaceutical approaches. By creating a more seamless connection between clinical trials and real-world implementation, the partnership aims to accelerate the delivery of innovative therapeutic options to patients.
Market Context and Future Direction
The digital therapeutics market has been gaining momentum as evidence mounts for the efficacy of software-based interventions. These solutions can potentially address gaps in traditional care models, improve medication adherence, and provide ongoing support between clinical visits.
For Dassault Systèmes (搜索), this investment aligns with its broader strategy of expanding its healthcare footprint. The company has been actively developing its capabilities in life sciences, including its Living Heart Project and other virtual twin technologies that simulate biological systems.
The partnership between Dassault Systèmes (搜索)' MEDIDATA and Click Therapeutics (搜索) represents a significant advancement in bridging the gap between clinical development and commercial implementation of digital therapeutics, potentially reshaping how patients experience healthcare beyond the traditional clinical trial environment.